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from a cumulative of 73 per 10.000 patient-days to a rate of
23.8 per 10.000 patient-days, with no new cases during the
last month of surveillance.
Conclusion: A multidisciplinary approach to decrease rates
of CDI including: education, enhanced environmental
cleaning with review and feedback, and standard use of UVC
pulsed technology was effective to reduce the rates of CDI in
a bone marrow transplant unit.367
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Growth factors are routinely used after autologous
transplantation to shorten the duration of neutropenia.
Tbo-ﬁlgrastim (TBO) was recently approved in the U.S. for
patients with non-myeloid malignancies. The Average
Wholesale Price for TBO is 20% less than Filgrastim (FGS).
Whether TBO is comparable to FGS for reducing time to
engraftment following HSCT is unknown. A cost-savings
initiativewas undertaken at NorthwesternMemorial Hospital
to substitute TBO for FGS in all autografts. Herein are the re-
sults of an observational study which compares TBO and FGS.
FGS patients were treated from10/2013-4/14/2014 and TBO
patients between 4/15/14-9/20/2014. All patients were
treated for multiple myeloma with melphalan 200mg/m2.
TBO and FGS were initiated day+5 after stem cell infusion,
and discontinued the ﬁrst day the absolute neutrophil
exceeded 1000/ml. Time to engraftment was deﬁned as
the number of days from stem cell re-infusion until the
ﬁrst day the ANC exceeded 500cell/ml. TBO and FGS dose
was rounded as follows: <80kg received 300mcg/day,
>80mg<120kg received 480mcg and those >120kg received
600mcg/day.
96 consecutively treatedpatientswere included-48 treated
with TBO and 48 treated with FGS. No signiﬁcant differenceTable 1
Filgrastim versus TBO-ﬁlgrastim
Characteristic (median/range) Filgrastim TBO-Filgastim P-value
Number 48 48
Age 57(42-69) 59(38-69) 0.9299
Gender (male/%) 27(56) 30(52) 0.8395
Weight (kg) 76(47-120) 84(50-160) 0.1227
Body surface area (adjusted) 1.8(1.45-2.2) 1.8(1.45-2.25) 0.8755
Melphalan dose (mg) 365(290-440) 365(290-45) 0.99
G-CSF dose(mcg/kg) 389(300-600) 413(300-600) 0.2584
Number of CD34 stem cell
infused
(million/kg) 6.57(2.97-20.9) 7.04(3.6-19.1) 0.4621
Documented infection (%) 6(12.5) 3(6) 0.468
Febrile neutropenia (%) 27(56) 20(41) 0.2204
Time to engraftment (days) 12(9-23) 13 (10-26) 0.0338
Engraftment > 14days (%) 8(17) 16(33) 0.0521
Total number of G-CSF doses
(mean/days)
9.42(6-24) 9.8(5-24) 0.5109
Length of stay(days) 16(13-51) 16(12-27) 0.4118
Elevated temps(>100.5) for
> 48 hours
9(19) 5(10) 0.3864
Hospital mortality 0 1 0.99was observed for diagnosis, age, gender, weight, BSA, growth
factor dose or dose/kg, number of stem cells infused, number
of patients who developed febrile neutropenia or micro-
biologically proven infection or prolonged fever (>48 hours).
Median time to engraftment and delayed engraftment
(>14days) was signiﬁcantly longer in the TBO-treated
patients. There was no difference in overall length of stay or
hospital mortality.
TBO-ﬁlgastrim appears to be effective in reducing the time
of neutropenia and stem cell engraftment. However delayed
engraftment, especially as observed >14 days after stem cell
infusion,was observed signiﬁcantlymore often inTBO treated
patients compared to those treated with FGS. These results
require conﬁrmation through a large randomized trial.368
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Allogeneic hematopoietic stem cell transplantation is being
employed as a life-saving procedure for greater numbers of
patients each year. Outpatient, reduced intensity transplants
and haplo-matched transplants, recognition of limited efﬁ-
cacy for chemotherapy in high risk diseases, and extending
the age limit for adults have all contributed to the growing
numbers. As a consequence, the demand for donor screening
resources has also increased. The National Marrow Donor
Programs (NMDP) has published the Assessment Tool at
Workup that has been recommended for use in determining
eligibility of unrelated donors. In order to avoid the risk of
bias in determining eligibility of related donors, the same
criteria are being applied to them at many centers. As a
referral center for complex transplants and increasing
numbers of donors, we reviewed the outcomes of related
donor screening and need for “additional” testing.
All donors were evaluated through a nurse practitioner-
based clinic with physician backup. All donors were
evaluated for bone marrow as well as peripheral blood
donation regardless of the requested product. Sixty-two
related potential donors were screened at MSKCC from
February through September 2014. The median age was
48yrs and they were equally divided between males and
females. Their demographics and outcomes are described in
Table 1. Based on initial routine screening studies and
utilizing the NMDP guidelines 15 donors (24%) were deemed
eligible and cleared for donation; 6 were ineligible according
to the NMDP guidelines for the following diagnoses: sickle
cell trait, systemic lupus, multiple sclerosis, history of
cervical cancer, babesiosis, and brain arteriovenous
malformation. Forty-seven (76%) donors did not clear
initially and 45 required additional evaluation based on  1
abnormalities (Table 2). These may have included laboratory
or imaging studies, informal or formal subspecialty
consultation or “other studies” such as bone marrow
procedure. Notably only 1/14 foreign born donors cleared
following initial evaluation. Forty-four (71%) donors actually
donated, 4 of whom were deemed ineligible but were used.
In all but 13 cases, the additional testing led to clearance.
